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c-KIT and  
You Shall Find It
Childhood-onset mastocytosis, 
which involves abnormal 
mast cell accumulation in 
various tissues, often regresses 
spontaneously. Bodemer and 
colleagues discovered mutations 
in c-KIT in 86% of 50 pediatric 
patients examined. Forty-two 
percent of these patients had a 
mutation in codon 816, which 
is commonly mutated in clonal 
adult-onset mastocytosis. 
These mutations resulted in 
constitutively activated c-KIT. 
Although no obvious correlations 
were reported between the 
mutations and clinical phenotype, 
researchers hope that additional 
studies will illuminate a 
predictive relationship between 
the mutation and the future 
regression of this childhood 
disease. See page 804
The Pressures  
of Aging
Elderly patients are more prone to 
develop pressure ulcers, although 
the underlying reasons are 
uncertain. Fromy and colleagues 
discovered that in older patients 
with peripheral neuropathy, 
pressure-induced vasodilation, 
which protects the skin from 
pressure-induced ischemic 
damage, was completely absent. 
Similar yet less profound changes 
were observed in nonneuropathic 
older patients. Abnormal small 
sensory fibers, rather than 
endothelial function, were 
responsible for these changes. 
Therefore, older subjects with a 
severe sensory deficit are at risk 
for pressure ulcer development 
as a result of loss of pressure-
induced vasodilation and the lack 
of a sensory warning system.  
See page 849
Thickness Trends
Although the frequency of malig-
nant melanoma has continued to rise, 
its overall mortality has stabilized. 
Criscione and Weinstock analyzed 
melanoma tumor thickness for some 
153,000 cases from the Surveillance 
Epidemiology and End Result program. 
The proportions of thickness categories 
remained constant over the 19-year 
study period, but the proportion of 
thick tumors increased among melano-
mas causing death. It appears that the recent emphases on skin self-examination and der-
matologist screenings, intensified educational efforts, and improved diagnostic accuracy 
have increased the number of diagnosed thin malignant melanomas in some European 
countries, but they have failed to affect the rates in the United States and Australia, dem-
onstrating a need for even better screening efforts. See page 793
Pigmentation Regulation
Although the biochemical pathway involved 
in melanin synthesis has been identified, infor-
mation about factors involved in this process 
is lacking. Choi and colleagues employed oli-
gonucleotide microarrays and matrix-assisted 
laser desorption ionization–time of flight mass 
spectrometry to identify genes differentially 
expressed in acral lentiginous melanoma cells. 
Among the genes identified, that for NAD(P)
H:quinine oxidoreductase-1 (NQO1) was 
found to be a positive regulator of melano-
genesis. This flavoenzyme exerts its role in the 
cellular defense mechanism against oxidative 
stress. A decrease in NQO1 levels, which was observed in many melanoma lines, may 
predispose melanocytes to cancer. In addition, overexpression of NQO1 enhanced pig-
mentation, probably through stabilization of tyrosinase, the rate-limiting enzyme in mel-
anogenesis. Identification of this novel regulator brings us one step closer to understand-
ing the process of pigmentation. See page 784
Identification of the Scleroderma Signature
Because transforming growth factor-β (TGF-β) has pre-
viously been implicated in fibrosis in systemic sclerosis, 
Sargent and colleagues experimentally characterized a 
mechanism-derived TGF-β gene signature in fibroblasts 
from scleroderma patients and healthy individuals. This 
TGF-β-responsive signature was associated with the 
“diffuse-proliferation” subset of patients having system-
ic sclerosis with diffuse scleroderma. These results support the identification of patient 
subsets via gene expression patterns and indicate that TGF-β or related pathways may 
underlie diffuse-proliferation scleroderma. See page 694
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